The $385 million settlement approved in February 2024 resolves a major antitrust case against Indivior and Reckitt Benckiser Pharmaceuticals for their deliberate manipulation of the Suboxone market. The settlement targets direct purchasers of Suboxone tablet products between January 1, 2012, and March 14, 2013—the period when Indivior executed an aggressive strategy to eliminate generic competition by switching patients from tablets to sublingual film formulations. Judge Mitchell S. Goldberg of the U.S. District Court for the Eastern District of Pennsylvania granted final approval on February 27, 2024, after the class showed an “overwhelmingly favorable” response with zero objections from class members, a rare achievement that signals broad agreement on the settlement’s fairness.
The antitrust violation at the heart of this case is straightforward but consequential: Indivior couldn’t prevent generic manufacturers from producing Suboxone tablets because they’re chemically identical to the branded version. However, by discontinuing tablets in 2013 and raising their prices significantly before the switch, the company forced prescribers and patients toward the branded film product, which generics couldn’t replicate. This maneuver prevented pharmacy-level generic substitution and maintained Indivior’s monopoly control over the market during a critical period when addiction treatment demand was surging. Eligible direct purchasers—primarily wholesalers, pharmacies, and other entities that bought Suboxone tablets from Indivior during the settlement period—can now pursue compensation through the class action process. The settlement also reflects broader fallout from Indivior’s conduct: separate settlements totaling over $517 million have been reached with healthcare payors and state attorneys general for related fraud and antitrust claims, making the Suboxone litigation one of the pharmaceutical industry’s most expensive antitrust matters.
Table of Contents
- What Was Indivior’s Anti-Competitive Conduct in the Suboxone Market?
- How the $385 Million Settlement Compensates Direct Purchasers
- Related Settlements and Other Legal Actions Against Indivior
- Understanding Dental Injury Claims and Separate Litigation
- How to Determine If You’re an Eligible Direct Purchaser
- The Broader Context of Pharmaceutical Antitrust Litigation
- What Happens Next and Future Implications
- Conclusion
What Was Indivior’s Anti-Competitive Conduct in the Suboxone Market?
Indivior’s strategy was pharmaceutical market manipulation at its clearest. The company faced a real competitive threat: buprenorphine, the active ingredient in Suboxone, was a decades-old opioid medication used for addiction treatment. When buprenorphine became increasingly popular for opioid-use disorder treatment in the late 2000s and early 2010s, generic manufacturers stood ready to produce cheaper tablet versions. Under normal FDA substitution rules, pharmacists could swap a patient’s branded Suboxone tablet prescription for a generic equivalent without contacting the prescriber, directly threatening Indivior’s pricing power. The company’s response was to reformulate Suboxone as a sublingual film—a dissolvable strip placed under the tongue—and discontinue the tablet form. This wasn’t innovation driven by patient need; it was deliberate market control.
Unlike tablets, sublingual film couldn’t be automatically substituted with generics because the FDA’s bioequivalence rules treat different dosage forms differently. A pharmacy couldn’t swap film for tablets at the counter. Additionally, Indivior raised tablet prices significantly in the years before discontinuation, making the switch to film seem inevitable to both cost-conscious prescribers and patients. For example, patients and payors who depended on Suboxone for addiction treatment during this period faced higher out-of-pocket costs or formulary restrictions due to the artificially inflated tablet pricing—a direct harm to some of the most vulnerable populations seeking opioid treatment. The timing was strategic. The class period ends March 14, 2013, just months before Indivior discontinued tablets entirely, locking in the anti-competitive effects and establishing film as the only available form going forward.
How the $385 Million Settlement Compensates Direct Purchasers
The $385 million settlement awarded to direct purchasers is structured to compensate the businesses and entities that bore the economic harm of Indivior’s anti-competitive conduct. Direct purchasers include wholesalers, hospital systems, pharmacy chains, and other institutions that purchased Suboxone tablets directly from Indivior during the January 2012 to March 2013 class period. These entities paid supracompetitive prices due to Indivior’s artificial elimination of generic competition—prices that would have been substantially lower if the tablet market had remained competitive. Unlike consumer settlements, which distribute money to individual patients, direct purchaser settlements compensate the commercial entities that took the economic hit. The approval process for the settlement was notably smooth.
Judge Goldberg’s final approval order on February 27, 2024, noted the “overwhelmingly favorable” class response, an unusual circumstance that reflects strong agreement among eligible purchasers that the settlement amount fairly represents the overcharges they sustained. The absence of objections—a common phenomenon in contentious class actions—suggests that the settlement’s terms and compensation formula were viewed as reasonable by the class members themselves. This doesn’t mean every purchaser received identical compensation; the settlement uses a claims process where eligible direct purchasers can document their purchases and receive proportional awards based on their purchase volume and timing. A critical limitation to understand: not all entities that purchased Suboxone tablets are eligible direct purchasers. Indirect purchasers—entities that bought from wholesalers rather than directly from Indivior, or consumers who bought from pharmacies—are generally excluded from this settlement. However, indirect purchasers are not without recourse; separate consumer-focused litigation and state-level settlements address their claims.
Related Settlements and Other Legal Actions Against Indivior
The $385 million direct purchaser settlement is part of a much larger constellation of legal consequences Indivior has faced for the same conduct. In August 2023, the company settled with health plans (including major players like Blue Cross Blue Shield of Massachusetts, Health Care Service Corporation, Blue Cross Blue Shield of Florida, and Molina Healthcare) for $85 million, compensating these organizations for the higher costs they bore due to artificially inflated Suboxone prices and the forced switch to film formulations. That same year, in June 2023, Indivior agreed to a $102.5 million multistate settlement with 41 state attorneys general plus Washington D.C., addressing both antitrust and consumer protection claims stemming from the same conduct. Even more significantly, in 2021, Indivior paid $300 million to all 50 states and the District of Columbia to settle charges of false marketing and fraud related to Suboxone.
That settlement focused on misleading claims about the abuse-resistant properties of the film formulation compared to tablets, a claim that regulators and state attorneys found unsupported. Combined, these settlements total over $572 million, making the Suboxone litigation one of the costliest pharmaceutical antitrust and fraud cases in recent memory. For eligible parties, this means multiple potential compensation pathways: a direct purchaser might also qualify for health plan relief if their entity is a covered payor, or a state might have established its own restitution program with Indivior settlement funds. The layering of settlements also reveals the scope of Indivior’s misconduct. It wasn’t just an antitrust problem; it involved coordinated false claims, inadequate disclosure of the company’s anti-competitive intent, and systematic deception across multiple stakeholder groups.
Understanding Dental Injury Claims and Separate Litigation
While the $385 million settlement resolves the direct purchaser antitrust claims, a separate and ongoing mass tort lawsuit addresses a different Suboxone harm: severe dental damage. Suboxone film users have reported significant tooth decay, enamel erosion, and other oral injuries, apparently linked to the film’s acidity and the way it dissolves against teeth over time. This litigation is distinct from the antitrust settlement because it focuses on personal injury, not market manipulation—a crucial distinction that affects eligibility and compensation structures. As of March 18, 2026, a U.S. District Court entered an order approving distribution of settlement funds in the dental injury litigation, indicating that some compensation pathway is finally becoming available for affected patients.
The estimated payout ranges for dental injury claims provide concrete figures: minor to moderate tooth damage qualifies for $10,000 to $50,000, more extensive damage involving multiple teeth or root canals falls in the $50,000 to $150,000 range, and severe cases requiring extensive dental reconstruction or implants can reach $150,000 to $500,000 or more, depending on the extent of harm and medical documentation provided. However, the dental litigation has progressed more slowly than the antitrust settlement, and the final resolution remains ongoing. A critical distinction for potential claimants: you cannot typically receive compensation through both the direct purchaser antitrust settlement and the dental injury litigation if you’re an individual consumer. If you purchased Suboxone tablets during the class period and suffered dental injuries, you’d pursue the dental claim, not the antitrust claim (which is designed for commercial purchasers). If you’re a pharmacy, hospital, or wholesaler that purchased directly from Indivior, you’d pursue the direct purchaser claim. This overlap explains why the settlements have different structures and timelines.
How to Determine If You’re an Eligible Direct Purchaser
Eligibility for the $385 million direct purchaser settlement requires that you or your organization purchased Suboxone tablets directly from Indivior Pharmaceuticals between January 1, 2012, and March 14, 2013. This means you must have had a direct commercial relationship with Indivior—not a wholesaler or another middleman—and purchased during the specified class period. Most eligible entities fall into these categories: pharmaceutical wholesalers (the primary distributors to pharmacies), hospital pharmacies and health systems that procured directly from Indivior, pharmacy chains with direct purchasing agreements, and large retailers with pharmacy departments that maintained direct vendor relationships. To file a claim, you’ll need documentation of your purchases: invoices, purchase orders, payment records, or account statements showing Suboxone tablet purchases from Indivior during the class period. The claims administrator will ask you to quantify your total tablet purchases during the 16-month class window and may request supporting documentation.
The settlement’s pro-rata distribution formula means that entities with larger purchase volumes receive larger compensation, proportional to their share of total eligible purchases across the entire class. One important warning: the claims process has filing deadlines, typically months after final approval, so delaying can result in forfeited claims. If you operated a pharmacy in 2012-2013 and purchased Suboxone tablets, check your records now and monitor settlement websites for claim deadline notices. For entities that may have indirect evidence of purchases (such as payment records but not detailed invoices), the claims administrator may request additional documentation or affidavits attesting to the purchases. This process can be time-consuming, but most claims administrators are accustomed to working with limited documentation and will make reasonable efforts to verify purchase claims based on available records.
The Broader Context of Pharmaceutical Antitrust Litigation
The Suboxone antitrust case reflects a growing enforcement trend against pharmaceutical manufacturers who use regulatory pathways and reformulation strategies to block generic competition. The FDA’s drug approval system, while designed to ensure safety, can inadvertently create leverage for brand-name manufacturers to extend monopolies beyond the original patent life. Changing a drug’s formulation—from tablets to film, from twice-daily dosing to once-daily, from oral to injectable—creates new regulatory approvals, new patent protections, and crucially, new markets where generics may not yet exist.
Indivior’s conduct in the Suboxone case exemplifies what regulators now scrutinize: the deliberate timing of price increases and discontinuations designed to force market transition toward a reformulated product rather than organic patient preference. Similar litigation has targeted other pharmaceutical companies’ reformulation strategies, including cases involving popular medications for diabetes, hypertension, and pain management. The Suboxone settlement therefore serves as a cautionary tale and a precedent for both enforcement action and civil litigation against similar conduct in other drug markets.
What Happens Next and Future Implications
The approval of the $385 million settlement in February 2024 closes one chapter of the Suboxone litigation, but the dental injury litigation and residual claims from other state or federal proceedings continue. Class members who believe they qualify should monitor the claims process closely, as settlement funds are typically distributed within one to two years of final approval if claims are filed promptly. The completion of this settlement also removes one major legal overhang for Indivior, though the company continues to face reputational damage in addiction medicine communities and remains subject to ongoing regulatory scrutiny.
Looking forward, the Suboxone litigation’s outcomes will likely influence how pharmaceutical regulators and enforcement agencies evaluate product reformulations, pricing strategies around discontinuations, and corporate conduct in addiction treatment markets. The case demonstrates that even in critical therapeutic areas—where patient access is vital—manufacturers cannot use regulatory systems to eliminate competition at the expense of affordability and market integrity. For future purchasers and patients of addiction-treatment medications, the precedent established here should create stronger incentives for manufacturers to compete on efficacy and convenience rather than market manipulation.
Conclusion
The $385 million settlement approved on February 27, 2024, represents a substantial recovery for direct purchasers harmed by Indivior’s antitrust violations in the Suboxone market. By switching from tablets to sublingual film and strategically discontinuing the generic-competitive tablet form, Indivior maintained supracompetitive pricing and eliminated choice during a period of critical opioid-use disorder treatment demand. The settlement’s “overwhelmingly favorable” class response and zero objections underscore the broad agreement that the compensation fairly addresses the economic harm inflicted on wholesalers, pharmacies, hospitals, and other direct purchasers during the 16-month class period.
If you believe you or your organization qualifies as a direct purchaser of Suboxone tablets between January 1, 2012, and March 14, 2013, gather your purchase documentation and file a claim before the deadline. Separately, if you’re an individual who used Suboxone film and suffered dental injuries, monitor the ongoing dental injury litigation for further compensation opportunities. Together, these settlements and lawsuits demonstrate that pharmaceutical antitrust enforcement is real, meaningful, and available to those harmed by anti-competitive conduct.